Passage Bio Inc. (PASG): Price and Financial Metrics
PASG Price/Volume Stats
| Current price | $0.66 | 52-week high | $1.79 |
| Prev. close | $0.65 | 52-week low | $0.45 |
| Day low | $0.60 | Volume | 3,183,300 |
| Day high | $0.72 | Avg. volume | 353,183 |
| 50-day MA | $0.66 | Dividend yield | N/A |
| 200-day MA | $0.93 | Market Cap | 40.77M |
PASG Stock Price Chart Interactive Chart >
Passage Bio Inc. (PASG) Company Bio
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
PASG Price Returns
| 1-mo | 23.13% |
| 3-mo | -3.08% |
| 6-mo | -27.47% |
| 1-year | -33.08% |
| 3-year | -90.15% |
| 5-year | N/A |
| YTD | -34.65% |
| 2023 | -26.81% |
| 2022 | -78.27% |
| 2021 | -75.17% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...